Nels Eric Olson

TL;DR: In this article, the authors present methods for determining if a subject is at risk for developing neurotoxicity following administration of a therapy, such as an immunotherapy or cell therapy, e.g., a chimeric antigen receptor (CAR) T cell therapy based on the expression, in a sample obtained from the subject, of one or more genes or gene products that are associated with and/or correlate to a risk of developing toxicity following the therapy.